Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT

Bone Marrow Transplantation volume 58, pages 791–800 (2023)Cite this article

Subjects

Abstract

We compared transplants (HSCT) from matched related siblings (MSD) with those from matched 10/10 and mismatched 9/10 unrelated (UD) and T-replete haploidentical (Haplo) donors in acute myeloid leukemia (AML) in first complete remission (CR1) achieved after two inductions, a known poor prognostic factor. One thousand two hundred and ninety-five patients were included: MSD (n = 428), UD 10/10 (n = 554), UD 9/10 (n = 135), and Haplo (n = 178). Acute GVHD II–IV was higher in all groups compared to MSD. Extensive chronic (c) GVHD was significantly higher in UD 9/10 (HR = 2.52; 95% CI 1.55–4.11, p = 0.0002) and UD 10/10 (HR = 1.48; 95% CI 1.03–2.13, p = 0.036) and cGVHD all grades were higher in UD 9/10 vs MSD (HR = 1.77; 95% CI 1.26–2.49, p = 0.0009). Non-relapse mortality was higher in all groups compared to MSD. Relapse incidence, leukemia-free, and overall survival did not differ significantly between donor types. Finally, GVHD-free relapse-free survival was lower in HSCT from UD 9/10 (HR = 1.56, 95% CI 1.20–2.03, p = 0.0009) but not in those from UD 10/10 (HR = 1.13, p = 0.22) and Haplo donors (HR = 1.12, p = 0.43) compared to MSD. In conclusion, in AML patients undergoing HSCT in CR1 achieved after two induction courses 10/10 UD and Haplo but not 9/10 UD donors are comparable alternatives to MSD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Five-year transplantation outcome in patients with acute myeloid leukemia achieving first complete remission after two induction courses: matched related versus matched or mismatched unrelated versus haploidentical donors.

Similar content being viewed by others

Data availability

AN, ML and MM had full access to all study data (available upon data-specific request).

References

  1. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–52.

    Article  PubMed  Google Scholar 

  2. Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, et al. Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy. Transplant Cell Ther. 2021;27:6–20.

    Article  CAS  PubMed  Google Scholar 

  3. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, et al. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021;8:e205–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F. et al. Prediction of allogeneic hematopoietic stem-cell transplantation mortality 100 days after transplantation using a machine learning algorithm: a European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. J Clin Oncol. 2015;33:3144–51.

    Article  PubMed  Google Scholar 

  6. Shouval R, Fein JA, Shouval A, Danylesko I, Shem-Tov N, Zlotnik M, et al. External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019;3:1881–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Nagler A, Ngoya M, Galimard JE, Labopin M, Bornhäuser M, Stelljes M, et al. Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis. Clin Cancer Res. 2022;28:4258–66. clincanres.0809.2022-3-14 14:38:43.713.

  8. Burnett AK, Goldstone A, Hills RK, Milligan D, Prentice A, Yin J, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol. 2013;31:1293–301.

    Article  PubMed  Google Scholar 

  9. Gilleece MH, Labopin M, Savani BN, Yakoub-Agha I, Socié G, Gedde-Dahl T, et al. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. Leukemia. 2020;34:87–99.

    Article  CAS  PubMed  Google Scholar 

  10. Nagler A, Baron F, Labopin M, Polge E, Esteve J, Bazarbachi A, et al. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplant. 2021;56:218–24.

    Article  PubMed  Google Scholar 

  11. Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol. 2018;93:1142–52.

    Article  PubMed  Google Scholar 

  12. Sharvit G, Heering G, Zlotnik M, Merkel D, Nagler A, Avigdor A, et al. Acute myeloid leukemia patients requiring two cycles of intensive induction for attainment of remission experience inferior survival compared with patients requiring a single course of induction chemotherapy. Clin Lymphoma Myeloma Leuk. 2022;22:e116–23.

    Article  CAS  PubMed  Google Scholar 

  13. Nagler A, Labopin M, Huang XJ, Blaise D, Arcese W, Araujo MC, et al. Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplant. 2022;57:572–8.

    Article  CAS  PubMed  Google Scholar 

  14. Nagler A, Galimard JE, Labopin M, Blaise D, Arcese W, Trisolini SM. et al. Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: a study from the ALWP of the EBMT. Cancer Med. 2023;12:1482–91. https://doi.org/10.1002/cam4.5039.

    Article  CAS  PubMed  Google Scholar 

  15. Walter RB, Sandmaier BM, Storer BE, Buckley SA, Pagel JM, Sorror ML, et al. Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. Biol Blood Marrow Transplant. 2015;21:373–8.

    Article  PubMed  Google Scholar 

  16. Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong ASM, Braley JA, et al. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021;137:1196–207.

    Article  CAS  PubMed  Google Scholar 

  17. Kawase T, Matsuo K, Kashiwase K, Inoko H, Saji H, Ogawa S, et al. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood. 2009;113:2851–8.

    Article  CAS  PubMed  Google Scholar 

  18. Crocchiolo R, Ciceri F, Fleischhauer K, Oneto R, Bruno B, Pollichieni S, et al. HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. Bone Marrow Transplant. 2009;44:571–7.

    Article  CAS  PubMed  Google Scholar 

  19. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.

    CAS  PubMed  Google Scholar 

  21. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinic pathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.

    Article  CAS  PubMed  Google Scholar 

  22. Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51:610–1.

    Article  CAS  PubMed  Google Scholar 

  23. Abraham SK, Arnon N, Bipin S. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2019;2:2–4.

    Article  Google Scholar 

  24. Andersen PK, Klein JP, Zhang MJ. Testing for center effects in multi-center survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489–500.

    Article  CAS  PubMed  Google Scholar 

  25. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2017. https://www.R-project.org/.

  26. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20:1975–81.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Piemontese S, Ciceri F, Labopin M, Arcese W, Kyrcz-Krzemien S, Santarone S, et al. Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. J Hematol Oncol. 2017;10:24.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;6:13. 46

    Google Scholar 

  30. Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, et al. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018;11:55.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Yu S, Huang F, Wang Y, Xu Y, Yang T, Fan Z, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multi center cohort study. Leukemia. 2020;34:1433–43.

    Article  CAS  PubMed  Google Scholar 

  32. Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J, et al. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. J Hematol Oncol. 2016;9:89.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Guo H, Chang YJ, Hong Y, Xu LP, Wang Y, Zhang XH. et al. Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cell Mol Immunol. 2021;18:1172–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Lu Y, Zhao YL, Zhang JP, Xiong M, Cao XY, Liu DY, et al. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status. Ann Hematol. 2020;99:2911–25.

    Article  CAS  PubMed  Google Scholar 

  35. Yu S, Huang F, Wang Y, Xu Y, Yang T, Fan Z, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2020;34:1433–43.

    Article  CAS  PubMed  Google Scholar 

  36. Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH, et al. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant. 2011;17:821–30.

    Article  PubMed  Google Scholar 

  37. Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10:134.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019;134:892–9.

    Article  CAS  PubMed  Google Scholar 

  39. Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019;6:e573–84.

    Article  PubMed  Google Scholar 

  40. Loke J, Labopin M, Craddock C, Niederwieser D, Cornelissen J, Afansayev B, et al. Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT. Bone Marrow Transplant. 2021;56:614–21.

    Article  CAS  PubMed  Google Scholar 

  41. Nagler A, Dholaria B, Labopin M, Bruno B, Rambaldi A, Pioltelli P, et al. The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. Bone Marrow Transplant. 2021;56:20–29.

    Article  CAS  PubMed  Google Scholar 

  42. Rubio MT, Savani BN, Labopin M, Polge E, Niederwieser D, Ganser A, et al. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party. J Hematol Oncol. 2016;9:65.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Canaani J, Labopin M, Itälä-Remes M, Blaise D, Socié G, Forcade E, et al. Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. Leukemia. 2019;33:1944–52.

    Article  CAS  PubMed  Google Scholar 

  44. Saraceni F, Labopin M, Forcade E, Kröger N, Socié G, Niittyvuopio R, et al. Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: a study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer Med. 2021;10:23–33.

    Article  PubMed  Google Scholar 

  45. Ringden O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients age >69 years with acute myelogenous leukemia: on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25:1975–83.

    Article  PubMed  Google Scholar 

  46. Nagler A, Dholaria B, Labopin M, Socie G, Huynh A, Itälä-Remes M, et al. The impact of anti-thymocyte globulin on the outcomes of patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. Leukemia. 2020;34:1144–53.

    Article  CAS  PubMed  Google Scholar 

  47. Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154–61.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J, et al. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. J Hematol Oncol. 2016;9:118.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Qayed M, Watkins B, Gillespie S, Bratrude B, Betz K, Choi SW, et al. Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation. Blood Adv. 2022;6:746–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Sourisseau M, Faure E, Béhal H, Chauvet P, Srour M, Capes A, et al. The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients. Blood Adv. 2023;7:856–65.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all the EBMT centers and national registries for contributing patients to this study (Supplementary Appendix material). We also thank the data managers for their excellent work.

Author information

Authors and Affiliations

  1. Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel

    Arnon Nagler

  2. EBMT Paris Study Office, Department of Hematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France

    Myriam Labopin & Mohamad Mohty

  3. Department of Hematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France

    Myriam Labopin & Mohamad Mohty

  4. Department of Cell Therapy and Allogeneic Stem Cell Transplantation (CAST), Department of Laboratory Medicine (LabMED), Karolinska University Hospital and Institutet, Karolinska Comprehensive Cancer Center, Stockholm, Sweden

    Stephan Mielke

  5. University Hospital Hematology, Basel, Switzerland

    Jakob Passweg

  6. Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France

    Didier Blaise

  7. Clinic for Cancer Medicine, Hematology Department, Section for Stem Cell Transplantation, Oslo University Hospital, Rikshospitalet, Oslo, Norway

    Tobias Gedde-Dahl

  8. Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands

    Jan J. Cornelissen

  9. HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland

    Urpu Salmenniemi

  10. CHU de Lille LIRIC, INSERM U995, Université de Lille, Lille, France

    Ibrahim Yakoub-Agha

  11. Department of Hematology and Stem Cell Transplant, Dél-pesti Centrumkórház – Országos Hematológiai és Infektológiai Intézet, Budapest, Hungary

    Péter Reményi

  12. Department of Hematology – BMT, Hôpital St. Louis, Paris, France

    Gerard Socié

  13. Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands

    Gwendolyn van Gorkom

  14. Centre Hospitalier Lyon Sud, Service Hematologie, Lyon, France

    Hélène Labussière-Wallet

  15. Peking University People’s Hospital, Institute of Haematology, Xicheng District, Beijing, China

    Xiao-Jun Huang

  16. CHRU BRABOIS, Vandoeuvre les Nancy, France

    Marie Thérèse Rubio

  17. Nottingham University Hospital, Nottingham, UK

    Jenny Byrne

  18. Department of Haematology, University Hospital Birmingham NHS Trust, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, UK

    Charles Craddock

  19. Vilnius University Hospital Santaros Klinikos, Haematology, Oncology & Transfusion Center, Vilnius, Lithuania

    Laimonas Griškevičius

  20. Hematology & Bone Marrow Transplant, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Fabio Ciceri

  21. Department of Hematology, Hospital Saint Antoine, EBMT Paris Study Office/CEREST-TC, Saint Antoine Hospital, Paris, France

    Mohamad Mohty

Authors
  1. Arnon Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Myriam Labopin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephan Mielke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jakob Passweg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Didier Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tobias Gedde-Dahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jan J. Cornelissen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Urpu Salmenniemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ibrahim Yakoub-Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Péter Reményi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Gerard Socié
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Gwendolyn van Gorkom
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hélène Labussière-Wallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Xiao-Jun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Marie Thérèse Rubio
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Jenny Byrne
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Charles Craddock
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Laimonas Griškevičius
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Fabio Ciceri
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Mohamad Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AN wrote the manuscript, designed the study, and interpreted the data. ML designed the study, performed the statistical analyses, interpreted the data, and edited the manuscript. MM designed the study, interpreted the data, and edited the manuscript. SM, JP, DB, TG-D, JJC, US, IY-A, PR, GS, GvG, HL-W, X-JH, MTR JB, CC, LG, and FC reviewed the manuscript and provided clinical data. All authors approved the final version of the manuscript.

Corresponding author

Correspondence to Arnon Nagler.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

The scientific boards of the ALWP of the EBMT approved this study.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nagler, A., Labopin, M., Mielke, S. et al. Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplant 58, 791–800 (2023). https://doi.org/10.1038/s41409-023-01980-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-023-01980-y

Search

Advanced search

Quick links